GHK-Cu and Bupropion Interaction: What Women Need to Know

What Are GHK-Cu and Bupropion, and Why Do Women Take Both?

These two agents show up together more often than you might expect, because the women who seek out GHK-Cu peptide protocols and the women who are prescribed bupropion overlap considerably in practice.

GHK-Cu is a naturally occurring copper-binding tripeptide (glycine-histidine-lysine complexed with copper II) first isolated from human plasma in 1973 by Pickart. Loren Pickart's original characterization is detailed in foundational biochemistry literature. Plasma concentrations fall from roughly 200 ng/mL in young adults to under 80 ng/mL by age 60, a decline that has spurred interest in topical and injectable formulations for wound healing, skin remodeling, and hair follicle stimulation. Compounding pharmacies dispense it under FDA 503A and 503B frameworks; it is not an FDA-approved drug.

Bupropion is an FDA-approved norepinephrine-dopamine reuptake inhibitor (NDRI) marketed as Wellbutrin SR/XL for major depressive disorder and seasonal affective disorder, Zyban for smoking cessation, and as a component of Contrave (bupropion/naltrexone) for weight management. The FDA label for bupropion hydrochloride extended-release can be reviewed on the FDA website.

Why Women Specifically Are Taking Both

Bupropion is prescribed to women across several distinct clinical scenarios:

• Reproductive-age women with major depression, especially where SSRIs cause sexual side effects or weight gain
• PCOS: bupropion's dopaminergic activity may support weight loss and reduce compulsive eating, though it is not first-line for PCOS per ACOG
• Perimenopausal women: bupropion is used off-label for vasomotor symptom-related mood disturbance and fatigue when hormone therapy is declined or contraindicated; The Menopause Society's 2023 position statement on non-hormonal therapies lists bupropion as a studied option for mood symptoms
• Women pursuing weight loss via Contrave alongside GLP-1 receptor agonists

GHK-Cu is popular among women for skin collagen density, female pattern hair loss (FPHL), and post-procedure healing. Injectable GHK-Cu is increasingly part of medical aesthetic and peptide longevity protocols, and many women manage these protocols themselves or through compounding prescribers who may not know about their psychiatric medications.

Pharmacology Deep-Dive: How Each Drug Works

Bupropion: Mechanism and CYP2D6 Inhibition

Bupropion inhibits the reuptake of dopamine and norepinephrine. It is primarily metabolized by CYP2B6 to its active metabolite hydroxybupropion, which carries most of the drug's antidepressant activity. The hepatic metabolism pathway via CYP2B6 is described in the published pharmacokinetic characterization of bupropion.

Critically for drug-drug interaction (DDI) purposes, bupropion and hydroxybupropion are potent inhibitors of CYP2D6. This matters because CYP2D6 metabolizes a wide range of drugs including opioids, antiarrhythmics, and certain antipsychotics. Women using tamoxifen for breast cancer risk reduction need to know that bupropion can reduce tamoxifen's conversion to its active metabolite endoxifen via CYP2D6 inhibition. A 2010 clinical pharmacology study quantified this interaction and its clinical relevance for breast cancer patients.

GHK-Cu: Mechanism and Pharmacokinetics

GHK-Cu works through copper-dependent enzymatic activity and direct receptor binding. It stimulates lysyl oxidase (essential for collagen and elastin crosslinking), activates matrix metalloproteinases, and has been shown in cell culture to modulate gene expression across more than 4,000 genes. A comprehensive review of GHK-Cu's gene-regulation activity was published in the journal Cosmetics.

What GHK-Cu does not do, based on current data, is undergo significant hepatic CYP-mediated metabolism. As a tripeptide, it is expected to be cleaved by plasma and tissue peptidases into its constituent amino acids (glycine, histidine, lysine) and free copper. No published human pharmacokinetic study has characterized its absorption, distribution, or clearance after subcutaneous injection in women. That evidence gap is real and should be stated plainly.

The Interaction Question: What the Evidence Actually Shows

No published human clinical trial, case report, or pharmacovigilance database entry (as of the date of this article's review) documents a confirmed pharmacokinetic or pharmacodynamic drug-drug interaction between GHK-Cu and bupropion. Searching PubMed for "GHK-Cu bupropion" returns zero results. Searching FDA FAERS for adverse events involving both agents together returns no signal in publicly available data.

That absence of evidence is not evidence of absence. It reflects the fact that GHK-Cu is a research-phase compound used mostly outside randomized controlled trials, meaning systematic interaction data simply have not been collected.

What we can do is assess theoretical interaction risk by mechanism, and that assessment belongs in three categories.

Category 1: CYP / Pharmacokinetic Interactions

GHK-Cu is a peptide cleaved by peptidases, not by cytochrome P450 enzymes. It is not known to inhibit or induce CYP2D6, CYP2B6, CYP3A4, or P-glycoprotein. Bupropion's metabolism via CYP2B6 and its inhibition of CYP2D6 are therefore not expected to be changed by GHK-Cu. This is a low-probability interaction pathway.

Category 2: Pharmacodynamic Interaction via Copper-Dopamine Biology

This is the mechanistically interesting pathway, and it is the reason a "no interaction" dismissal would be incomplete.

Copper is an essential cofactor for dopamine beta-hydroxylase (DBH), the enzyme that converts dopamine to norepinephrine in adrenergic neurons. The role of copper in DBH activity and catecholamine synthesis is established in human biochemistry literature. Bupropion acts by blocking reuptake of both dopamine and norepinephrine, tipping the balance toward dopaminergic signaling. If supplemental copper (delivered as GHK-Cu) were to meaningfully increase DBH activity in vivo, it could theoretically increase norepinephrine synthesis and modestly alter the dopamine/norepinephrine ratio that bupropion is trying to modulate.

Is this clinically significant? Probably not at typical GHK-Cu doses, for two reasons. First, DBH is not rate-limited by copper in a normally copper-replete person. Second, systemic copper delivery from typical GHK-Cu subcutaneous doses has not been quantified and is likely small relative to dietary copper intake (recommended dietary allowance for adult women: 900 mcg/day). Copper dietary reference intakes are published by the NIH Office of Dietary Supplements.

The theoretical signal exists. The clinical magnitude is unknown. This is the honest answer.

Category 3: Seizure Threshold Considerations

Bupropion carries a dose-dependent seizure risk. The incidence is approximately 0.1% at doses <450 mg/day for the standard-release formulation, rising to roughly 0.4% at doses approaching 600 mg/day. Seizure incidence data are detailed in the bupropion prescribing information and in a 1991 analysis in the Journal of Clinical Psychiatry. Seizure risk is higher in women with eating disorders (bulimia nervosa, anorexia nervosa), a history of head trauma, or CNS stimulant use.

Does GHK-Cu alter seizure threshold? No human data exist. Copper dysregulation (both copper excess and deficiency) has been associated with neurological symptoms in case reports. Wilson's disease, a condition of copper accumulation, is associated with neurological manifestations including seizures. The doses of copper in GHK-Cu formulations are not thought to cause systemic copper accumulation in healthy women, but there are no long-term safety studies.

If you are on bupropion for any indication, anything that could theoretically lower your seizure threshold warrants a conversation with your prescriber before you start it.

Sex-Specific Physiology: How Being a Woman Changes This Picture

Hormonal Fluctuations and Seizure Threshold

Seizure threshold is not static in women. Catamenial epilepsy is a well-characterized phenomenon in which seizure frequency increases in the perimenstrual or periovulatory phase, driven by the proconvulsant effect of estrogen and the anticonvulsant effect of progesterone. Catamenial epilepsy mechanisms and clinical patterns are reviewed in a Lancet Neurology publication.

For a woman on bupropion, this means her already-elevated seizure risk (relative to a man on the same dose) may fluctuate with her cycle. Adding any compound with uncertain CNS effects during the perimenstrual window, when progesterone has dropped and the protective GABAergic cushion is thinner, deserves thought.

Women in perimenopause face a different version of this. Estrogen fluctuation in perimenopause can lower seizure threshold, and perimenopausal women are increasingly prescribed bupropion for mood symptoms. Hormonal changes in perimenopause and their neurological implications are described in a review in Menopause journal.

Bupropion Pharmacokinetics in Women

Women generally have higher plasma concentrations of bupropion's active metabolite hydroxybupropion compared with men at equivalent doses. A sex-stratified pharmacokinetic analysis found that body weight and lean body mass differences account for most of this, but hormonal status may play an additional role. Sex differences in bupropion pharmacokinetics are noted in product labeling and referenced in population PK studies. Practically, women may reach seizure-risk territory at lower nominal doses than men, a fact rarely discussed in primary care settings.

PCOS and Metabolic Context

Women with PCOS who use bupropion (often for weight, mood, or binge-eating patterns) frequently also use peptide protocols for skin and hair, since FPHL and hormonal acne are common in PCOS. Copper serum levels in PCOS are inconsistently studied; one meta-analysis found elevated serum copper in women with PCOS compared with controls. A 2021 meta-analysis in Biological Trace Element Research reported elevated serum copper in PCOS. If copper metabolism is already dysregulated in PCOS, adding exogenous copper-containing peptide compounds adds an unknown variable.

Pregnancy and Lactation Safety

Bupropion in Pregnancy

Bupropion is FDA Pregnancy Category C. Human data are conflicting but concerning enough to require individualized discussion.

The GlaxoSmithKline bupropion pregnancy registry and subsequent population cohort studies have identified a possible association between first-trimester bupropion exposure and cardiovascular septal defects. A large Danish cohort study published in JAMA Psychiatry found a modest but statistically significant association between first-trimester bupropion exposure and ventricular septal defects. Other studies, including a 2022 meta-analysis in the British Journal of Clinical Pharmacology, found no significant increase in major malformations overall, but cardiac defects remain a signal that cannot be dismissed.

ACOG recommends that the decision to use antidepressants during pregnancy weigh untreated depression risk against fetal risk, with shared decision-making and the lowest effective dose. ACOG Practice Bulletin 92 on use of psychiatric medications during pregnancy and lactation supports individualized decision-making.

Plain statement: if you are pregnant or planning to conceive, do not start bupropion without a thorough conversation with your OB or MFM. If you are already on it, do not stop without the same conversation, because abrupt discontinuation of antidepressant therapy carries its own serious risks.

GHK-Cu in Pregnancy

There are no human safety data on GHK-Cu use during pregnancy. No animal reproduction studies designed to FDA standards have been published. Copper requirements increase modestly during pregnancy (from 900 mcg/day to 1,000 mcg/day RDA), but excess copper is teratogenic in animal models. Copper teratogenicity in animal models is referenced in NIH reproductive toxicology literature.

Plain statement: GHK-Cu should not be used during pregnancy given the complete absence of safety data. This is a compound-level recommendation, not a class-level one. Topical cosmetic products with trace GHK-Cu in creams are a different risk level than injectable compounded formulations and warrant separate discussion with your clinician.

Lactation

Bupropion transfers into breast milk. A 2009 study in Annals of Pharmacotherapy detected bupropion and hydroxybupropion in breast milk, with relative infant doses estimated below 2% of the maternal weight-adjusted dose. The LactMed database classifies bupropion as "probably compatible" with breastfeeding with monitoring for infant irritability.

GHK-Cu lactation data do not exist. Copper normally appears in breast milk at concentrations around 0.2 to 0.4 mg/L, declining over the course of lactation. Whether injectable GHK-Cu meaningfully raises breast milk copper has not been studied. Until data exist, injectable GHK-Cu should be avoided during lactation. Topical cosmetic use is likely of negligible systemic concern.

Who This Is Right For, and Who Should Pause

Women Who May Be Lower-Risk for This Combination

• You use only topical GHK-Cu skincare (cream concentrations), not injectable/subcutaneous compounded GHK-Cu
• You are on a stable, low-to-moderate bupropion dose (150 mg XL), have no seizure history, no eating disorder, and no high-risk CYP2D6 substrate in your regimen
• Your prescribing clinician knows about both agents and has reviewed your full medication and supplement list

Women Who Should Have a Dedicated Clinical Review Before Combining

• Any history of seizures or epilepsy, including catamenial epilepsy
• Active or recovered eating disorder (bupropion is contraindicated in bulimia nervosa and anorexia nervosa per the FDA label)
• Women using tamoxifen: bupropion's CYP2D6 inhibition is clinically significant here and adding a new variable is not advisable without pharmacist review
• Perimenopausal women on higher-dose bupropion where hormonal fluctuation is already destabilizing
• Women with PCOS who have documented copper level abnormalities
• Any injectable or subcutaneous GHK-Cu use (systemic copper exposure is uncharacterized)
• Pregnancy or breastfeeding (see section above)

Women Who Should Not Combine Them Without Specialist Input

• Women with Wilson's disease or any disorder of copper metabolism
• Women on bupropion doses above 300 mg/day combined with other seizure-threshold-lowering agents
• Women using GHK-Cu as part of a broader peptide stack that includes CNS-active compounds (e.g. Selank, semax) alongside bupropion

How to Have This Conversation With Your Prescriber

Your prescribers may not know each other's plans. A WomanRx clinician reviewing this combination would ask:

1. What is your bupropion formulation, dose, and how long have you been on it?
2. Is the GHK-Cu topical or injectable? What dose and frequency?
3. Do you have any seizure risk factors (eating disorder history, head trauma, alcohol use, concurrent stimulant use)?
4. Are you perimenopausal, and are your hormonal levels being monitored?
5. Do you have PCOS, and has anyone checked your serum copper?
6. Are you trying to conceive? If so, bupropion requires its own risk-benefit review and GHK-Cu injectable should stop.
7. What other medications and supplements are you taking, specifically any CYP2D6 substrates like codeine, tramadol, tamoxifen, or certain antipsychotics?

Bring this list to your next appointment. Write the answers down before you go.

Practical Monitoring if You Continue Both

If your clinician decides the combination is acceptable for you, these are reasonable monitoring parameters:

• Baseline and periodic serum copper and ceruloplasmin: not standard of care for bupropion alone, but reasonable if you are using injectable GHK-Cu regularly
• Symptom diary tracking: note any new or unusual neurological symptoms (headache, myoclonus, tremor, cognitive fog) and your menstrual cycle phase when they occur
• Bupropion dose review: confirm you are at the minimum effective dose; higher doses carry meaningfully higher seizure risk
• Annual CYP2D6 review: if you take any CYP2D6-sensitive medications alongside bupropion, pharmacogenomic testing may be worth discussing, since women with reduced CYP2D6 function accumulate higher bupropion metabolite levels